Norris Perne & French LLP MI raised its stake in Novartis AG (NYSE:NVS) by 0.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 64,416 shares of the company’s stock after buying an additional 512 shares during the period. Norris Perne & French LLP MI’s holdings in Novartis AG were worth $5,315,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of NVS. Integrated Investment Consultants LLC increased its stake in Novartis AG by 6.3% in the second quarter. Integrated Investment Consultants LLC now owns 1,240 shares of the company’s stock valued at $102,000 after buying an additional 74 shares in the last quarter. Iowa State Bank acquired a new stake in Novartis AG during the second quarter valued at approximately $122,000. Capital Analysts LLC increased its stake in Novartis AG by 3.5% in the second quarter. Capital Analysts LLC now owns 2,084 shares of the company’s stock valued at $172,000 after buying an additional 70 shares in the last quarter. Ledyard National Bank increased its stake in Novartis AG by 13.6% in the second quarter. Ledyard National Bank now owns 2,343 shares of the company’s stock valued at $193,000 after buying an additional 281 shares in the last quarter. Finally, Mechanics Bank Trust Department acquired a new stake in Novartis AG during the second quarter valued at approximately $206,000. 9.78% of the stock is owned by institutional investors.

Novartis AG (NYSE:NVS) traded up 0.76% during trading on Monday, reaching $79.94. 1,375,784 shares of the company traded hands. The company has a market cap of $190.35 billion, a PE ratio of 28.54 and a beta of 0.58. The company’s 50-day moving average is $80.86 and its 200 day moving average is $78.27. Novartis AG has a 12 month low of $69.90 and a 12 month high of $95.11.

Novartis AG (NYSE:NVS) last released its quarterly earnings data on Tuesday, July 19th. The company reported $1.23 EPS for the quarter, topping the Zacks’ consensus estimate of $1.18 by $0.05. Novartis AG had a net margin of 13.84% and a return on equity of 15.33%. The firm earned $12.47 billion during the quarter, compared to analysts’ expectations of $12.33 billion. During the same period in the previous year, the business posted $1.25 earnings per share. On average, analysts anticipate that Novartis AG will post $4.73 earnings per share for the current year.

Several research firms have commented on NVS. Citigroup Inc. reissued a “neutral” rating on shares of Novartis AG in a research report on Tuesday, May 24th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Novartis AG in a research report on Thursday, May 26th. Zacks Investment Research raised shares of Novartis AG from a “hold” rating to a “buy” rating and set a $92.00 target price for the company in a research report on Monday, July 11th. Bank of America Corp. restated a “hold” rating on shares of Novartis AG in a research note on Tuesday, July 12th. Finally, Argus restated a “hold” rating on shares of Novartis AG in a research note on Thursday, August 25th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $91.20.

Novartis AG Company Profile

Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s segments include Pharmaceuticals, Alcon and Sandoz.

5 Day Chart for NYSE:NVS

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with Analyst Ratings Network's FREE daily email newsletter.